company background image
300630 logo

Hainan Poly Pharm XSEC:300630 Stock Report

Last Price

CN¥6.81

Market Cap

CN¥3.1b

7D

-12.5%

1Y

-69.9%

Updated

31 Dec, 2024

Data

Company Financials

Hainan Poly Pharm. Co., Ltd

XSEC:300630 Stock Report

Market Cap: CN¥3.1b

300630 Stock Overview

Engages in the research and development, production, and sale of pharmaceutical drugs in China and internationally. More details

300630 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Hainan Poly Pharm. Co., Ltd Competitors

Price History & Performance

Summary of share price highs, lows and changes for Hainan Poly Pharm
Historical stock prices
Current Share PriceCN¥6.81
52 Week HighCN¥23.55
52 Week LowCN¥6.52
Beta0.19
1 Month Change-36.59%
3 Month Change-39.95%
1 Year Change-69.93%
3 Year Change-87.50%
5 Year Change-81.34%
Change since IPO-63.63%

Recent News & Updates

Recent updates

Shareholder Returns

300630CN PharmaceuticalsCN Market
7D-12.5%-0.08%1.0%
1Y-69.9%-6.0%8.2%

Return vs Industry: 300630 underperformed the CN Pharmaceuticals industry which returned -6% over the past year.

Return vs Market: 300630 underperformed the CN Market which returned 8.2% over the past year.

Price Volatility

Is 300630's price volatile compared to industry and market?
300630 volatility
300630 Average Weekly Movement12.6%
Pharmaceuticals Industry Average Movement6.7%
Market Average Movement8.1%
10% most volatile stocks in CN Market12.2%
10% least volatile stocks in CN Market5.1%

Stable Share Price: 300630's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: 300630's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
19921,565Min Hua Fanenglish.hnpoly.com

Hainan Poly Pharm. Co., Ltd. engages in the research and development, production, and sale of pharmaceutical drugs in China and internationally. The company’s formulations dosage forms comprise injections, tablets, capsules, dry suspensions/granules, eye drops and ointments, etc. covering various therapeutic areas, including cardiovascular, anti-allergy, antibiotics, gastrointestinal, dermatology, and non-steroid anti-inflammatory (NSAIDs). It offers pharmaceutical preparations and active pharmaceutical ingredients (APIs), other raw materials, excipients, prescription and non-prescription drugs, and contract manufacturing and contract development and manufacturing services.

Hainan Poly Pharm. Co., Ltd Fundamentals Summary

How do Hainan Poly Pharm's earnings and revenue compare to its market cap?
300630 fundamental statistics
Market capCN¥3.05b
Earnings (TTM)-CN¥106.04m
Revenue (TTM)CN¥1.31b

2.3x

P/S Ratio

-28.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300630 income statement (TTM)
RevenueCN¥1.31b
Cost of RevenueCN¥365.19m
Gross ProfitCN¥941.39m
Other ExpensesCN¥1.05b
Earnings-CN¥106.04m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Apr 21, 2025

Earnings per share (EPS)-0.24
Gross Margin72.05%
Net Profit Margin-8.12%
Debt/Equity Ratio96.7%

How did 300630 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 01:13
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hainan Poly Pharm. Co., Ltd is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yue GaoChangjiang Securities Co. LTD.
Zhizhong JingChina Merchants Securities Co. Ltd.
Jiaxi XuIndustrial Securities Co. Ltd.